Search

Your search keyword '"Fujita, Jiro"' showing total 976 results
Start Over Author "Fujita, Jiro" Language english
976 results on '"Fujita, Jiro"'

1. Invasive Haemophilus influenzae disease among adults in Japan during 2014–2018

Author

Hachisu, Yushi, Tamura, Kosuke, Murakami, Koichi, Fujita, Jiro, Watanabe, Hiroshi, Tanabe, Yoshinari, Kuronuma, Koji, Kubota, Tetsuya, Oshima, Kengo, Maruyama, Takaya, Kasahara, Kei, Nishi, Junichiro, Abe, Shuichi, Nakamura, Masahiko, Kubota, Mayumi, Hirai, Shinichiro, Ishioka, Taisei, Ikenoue, Chiaki, Fukusumi, Munehisa, Sunagawa, Tomimasa, Suzuki, Motoi, Akeda, Yukihiro, and Oishi, Kazunori

Published
2023
Full Text
View/download PDF

2. A Food Impaction in Crohn’s Ileal Stricture

Author

Hokama, Akira, Kishimoto, Kazuto, Ihama, Yasushi, Chinen, Hiroshi, Kinjo, Fukunori, and Fujita, Jiro

Subjects
Crohn's disease, computed tomography, small bowel obstruction., Medicine, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Published
2010

6. Pneumococcal meningitis in adults in 2014–2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan

Author

Chang, Bin, Tamura, Kosuke, Fujikura, Hiroyuki, Watanabe, Hiroshi, Tanabe, Yoshinari, Kuronuma, Koji, Fujita, Jiro, Oshima, Kengo, Maruyama, Takaya, Abe, Shuichi, Kasahara, Kei, Nishi, Junichiro, Kubota, Tetsuya, Kinjo, Yuki, Serizawa, Yusuke, Shimbashi, Reiko, Fukusumi, Munehisa, Shimada, Tomoe, Sunagawa, Tomimasa, Suzuki, Motoi, and Oishi, Kazunori

Published
2022
Full Text
View/download PDF

7. Autoimmune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation: significance of detecting reticulated platelets and glycoprotein-specific platelet autoantibodies

Author

Akuta, Keigo, Fukushima, Kentaro, Nakata, Keiichi, Hayashi, Satoru, Toda, Jun, Shingai, Yasuhiro, Tsutsumi, Kazuhito, Machida, Tomohisa, Hino, Akihisa, Kusakabe, Shinsuke, Doi, Yukiko, Fujita, Jiro, Kato, Hisashi, Maeda, Tetsuo, Yokota, Takafumi, Tomiyama, Yoshiaki, Hosen, Naoki, and Kashiwagi, Hirokazu

Published
2022
Full Text
View/download PDF

8. Clinical manifestations of hospitalized influenza patients without risk factors: A prospective multicenter cohort study in Japan via internet surveillance

Author

Ishida, Tadashi, Seki, Masafumi, Oishi, Kazunori, Tateda, Kazuhiro, Fujita, Jiro, Kadota, Jun-ichi, Kawana, Akihiko, Izumikawa, Koichi, Kikuchi, Toshiaki, Ohmagari, Norio, Yamada, Mitsuhiro, Maruyama, Takaya, Takazono, Takahiro, Miki, Makoto, Miyazaki, Yoshitsugu, Yamazaki, Yoshitaka, Kakeya, Hiroshi, Ogawa, Kenji, Nagai, Hideaki, and Watanabe, Akira

Published
2022
Full Text
View/download PDF

9. Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan

Author

Oka, Keisuke, Matsumoto, Akane, Tetsuka, Nobuyuki, Morioka, Hiroshi, Iguchi, Mitsutaka, Ishiguro, Nobuhisa, Nagamori, Tsunehisa, Takahashi, Satoshi, Saito, Norihiro, Tokuda, Koichi, Igari, Hidetoshi, Fujikura, Yuji, Kato, Hideaki, Kanai, Shinichiro, Kusama, Fumiko, Iwasaki, Hiromichi, Furuhashi, Kazuki, Baba, Hisashi, Nagao, Miki, Nakanishi, Masaki, Kasahara, Kei, Kakeya, Hiroshi, Chikumi, Hiroki, Ohge, Hiroki, Azuma, Momoyo, Tauchi, Hisamichi, Shimono, Nobuyuki, Hamada, Yohei, Takajo, Ichiro, Nakata, Hirotomo, Kawamura, Hideki, Fujita, Jiro, and Yagi, Tetsuya

Published
2022
Full Text
View/download PDF

13. Clinical manifestations of adult patients requiring influenza-associated hospitalization: A prospective multicenter cohort study in Japan via internet surveillance

Author

Ishida, Tadashi, Seki, Masafumi, Oishi, Kazunori, Tateda, Kazuhiro, Fujita, Jiro, Kadota, Jun-ichi, Kawana, Akihiko, Izumikawa, Koichi, Kikuchi, Toshiaki, Ohmagari, Norio, Yamada, Mitsuhiro, Maruyama, Takaya, Takazono, Takahiro, Miki, Makoto, Miyazaki, Yoshitsugu, Yamazaki, Yoshitaka, Kakeya, Hiroshi, Ogawa, Kenji, Nagai, Hideaki, and Watanabe, Akira

Published
2021
Full Text
View/download PDF

19. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017

Author

Shimbashi, Reiko, Suzuki, Motoi, Chang, Bin, Watanabe, Hiroshi, Tanabe, Yoshinari, Kuronuma, Koji, Oshima, Kengo, Maruyama, Takaya, Takeda, Hiroaki, Kasahara, Kei, Fujita, Jiro, Nishi, Junichiro, Kubota, Tetsuya, Tanaka-Taya, Keiko, Matsui, Tamano, Sunagawa, Tomimasa, and Oishi, Kazunori

Subjects
Vaccines, Polysaccharides, Adults, Health
Abstract

Streptococcus pneumoniae is a major cause of illness and death among adults (1). Pneumonia is the most common form of pneumococcal disease in adults, whereas invasive pneumococcal disease (IPD), including [...]

Published
2020
Full Text
View/download PDF

21. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for clinical microbiology in 2014: General view of the pathogens' antibacterial susceptibility

Author

Yanagihara, Katsunori, Matsumoto, Tetsuya, Aoki, Nobuki, Sato, Junko, Wakamura, Tomotaro, Kiyota, Hiroshi, Tateda, Kazuhiro, Hanaki, Hideaki, Ohsaki, Yoshinobu, Fujiuchi, Satoru, Takahashi, Manabu, Akiba, Yuji, Masunaga, Shingo, Takeuchi, Kenichi, Takeda, Hiroaki, Miki, Makoto, Kumagai, Toshio, Takahashi, Hiroshi, Utagawa, Mutsuko, Nishiya, Hajime, Kawakami, Sayoko, Ishigaki, Shinobu, Kobayasi, Nobuyuki, Takasaki, Jin, Mezaki, Kazuhisa, Iwata, Satoshi, Katouno, Yasuhiro, Inose, Rika, Niki, Yoshihito, Kawana, Akihiko, Fujikura, Yuji, Kudo, Makoto, Hirano, Tomo, Yamamoto, Masaki, Miyazawa, Naoki, Tsukada, Hiroki, Aso, Sakura, Yamamoto, Yoshihiro, Iinuma, Yoshitsugu, Mikamo, Hiroshige, Yamagishi, Yuka, Nakamura, Atsushi, Ohashi, Minoru, Kawabata, Atsushi, Sugaki, Yoshiko, Seki, Masafumi, Hamaguchi, Shigeto, Toyokawa, Masahiro, Kakeya, Hiroshi, Fujikawa, Yasunori, Mitsuno, Noriko, Ukimura, Akira, Miyara, Takayuki, Hayasi, Michio, Mikasa, Keiichi, Kasahara, Kei, Koizumi, Akira, Korohasi, Nobuyoshi, Matumoto, Takashi, Yosimura, Yutaka, Katanami, Yuichi, Takesue, Yoshio, Wada, Yasunao, Sugimoto, Keisuke, Yamamoto, Tsuyoshi, Kuwabara, Masao, Doi, Masao, Simizu, Satomi, Tokuyasu, Hirokazu, Hino, Satoshi, Negayama, Kiyoshi, Mukae, Hiroshi, Kawanami, Toshinori, Yatera, Kazuhiro, Fujita, Masaki, Kadota, Junichi, Hiramatsu, Kazufumi, Aoki, Yosuke, Magarifuchi, Hiroki, Oho, Megumi, Morinaga, Yoshitomo, Suga, Moritaka, Muranaka, Hiroyuki, Fujita, Jiro, Higa, Futoshi, and Tateyama, Masao

Published
2019
Full Text
View/download PDF

24. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma.

Author

Izutsu, Koji, Kumode, Takahiro, Yuda, Junichiro, Nagai, Hirokazu, Mishima, Yuko, Suehiro, Youko, Yamamoto, Kazuhito, Fujisaki, Tomoaki, Ishitsuka, Kenji, Ishizawa, Kenichi, Ikezoe, Takayuki, Nishikori, Momoko, Akahane, Daigo, Fujita, Jiro, Dinh, Minh, Soong, David, Noguchi, Hidehisa, Buchbjerg, Jeppe Klint, Favaro, Elena, and Fukuhara, Noriko

Abstract

Epcoritamab is a subcutaneously administered CD3xCD20 bispecific Ab that showed deep, durable responses with a manageable safety profile in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) in the global multicenter pivotal phase II trial EPCORE NHL‐1. Here, we present results from the similar EPCORE NHL‐3 phase I/II trial evaluating epcoritamab monotherapy in Japanese patients with R/R CD20+ B‐cell non‐Hodgkin's lymphoma previously treated with two or more lines of therapy. Epcoritamab was dosed subcutaneously in 28‐day cycles; once weekly during cycles 1–3, every 2 weeks during cycles 4–9, and every 4 weeks from cycle 10 until disease progression or unacceptable toxicity. Step‐up dosing and cytokine release syndrome (CRS) prophylaxis were used during treatment cycle 1. As of January 31, 2022, 36 patients received treatment with 48 mg epcoritamab monotherapy. At a median follow‐up of 8.4 months, overall response and complete response rates by independent review committee were 55.6% and 44.4%, respectively. The median duration of response, duration of complete response, and overall survival were not reached at the time of data cut‐off. The most common treatment‐emergent adverse events of any grade were CRS (83.3%), injection‐site reactions (69.4%), infections (44.4%), neutropenia (38.9%), hypokalemia (27.8%), and decreased lymphocyte count (25.0%). Cytokine release syndrome occurrence was predictable; events were primarily low grade (grade 1–2), all resolved, and none led to treatment discontinuation. These encouraging results are consistent with previous findings and support the ongoing clinical evaluation of epcoritamab for the treatment of R/R DLBCL, including in earlier treatment lines. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: General view of the pathogens' antibacterial susceptibility

Author

Yanagihara, Katsunori, Watanabe, Akira, Aoki, Nobuki, Matsumoto, Tetsuya, Yoshida, Masaki, Sato, Junko, Wakamura, Tomotaro, Sunakawa, Keisuke, Kadota, Junichi, Kiyota, Hiroshi, Iwata, Satoshi, Kaku, Mitsuo, Hanaki, Hideaki, Ohsaki, Yoshinobu, Fujiuchi, Satoru, Takahashi, Manabu, Takeuchi, Kenichi, Takeda, Hiroaki, Ikeda, Hideki, Miki, Makoto, Nakanowatari, Susumu, Takahashi, Hiroshi, Utagawa, Mutsuko, Nishiya, Hajime, Kawakami, Sayoko, Morino, Eriko, Takasaki, Jin, Mezaki, Kazuhisa, Chonabayashi, Naohiko, Tanaka, Chie, Sugiura, Hideko, Goto, Hajime, Saraya, Takeshi, Kurai, Daisuke, Katono, Yasuhiro, Inose, Rika, Niki, Yoshihito, Takuma, Takahiro, Kudo, Makoto, Ehara, Shigeru, Sato, Yoshimi, Tsukada, Hiroki, Watabe, Nobuei, Honma, Yasuo, Mikamo, Hiroshige, Yamagishi, Yuka, Nakamura, Atsushi, Ohashi, Minoru, Seki, Masafumi, Hamaguchi, Shigeto, Toyokawa, Masahiro, Fujikawa, Yasunori, Mitsuno, Noriko, Ukimura, Akira, Miyara, Takayuki, Nakamura, Takahito, Mikasa, Keiichi, Kasahara, Kei, Ui, Koji, Fukuda, Saori, Nakamura, Akihiro, Morimura, Mika, Yamashita, Mikio, Takesue, Yoshio, Wada, Yasunao, Sugimoto, Keisuke, Kusano, Nobuchika, Nose, Motoko, Mihara, Eiichirou, Kuwabara, Masao, Doi, Masao, Watanabe, Yaeko, Tokuyasu, Hirokazu, Hino, Satoshi, Negayama, Kiyoshi, Mukae, Hiroshi, Kawanami, Toshinori, Ota, Toshiyuki, Fujita, Masaki, Honda, Junichi, Hiramatsu, Kazufumi, Aoki, Yosuke, Fukuoka, Mami, Magarifuchi, Hiroki, Nagasawa, Zenzo, Kaku, Norihito, Fujita, Jiro, Higa, Futoshi, and Tateyama, Masao

Published
2017
Full Text
View/download PDF

36. Intratracheal Administration of Autologous Bone Marrow-Derived Cells Ameliorates Monocrotaline-Induced Pulmonary Vessel Remodeling and Lung Inflammation in Rats

Author

Yamazato, Yoriko, Yamazato, Masanobu, Ishida, Akio, Fujita, Jiro, and Ohya, Yusuke

Subjects
Bone marrow cells -- Physiological aspects -- Research, Inflammation -- Complications and side effects -- Care and treatment -- Research, Lung diseases -- Care and treatment -- Research, Health
Abstract

Purpose Inflammation is a feature of lung injury and plays a critical role in pulmonary vascular remodeling. Bone marrow-derived cells (BMCs) have anti-inflammatory properties and favor macrophage differentiation into an alternatively activated regulatory M2 profile. We investigated the effect of autologous BMCs on monocrotaline-induced pulmonary vessel remodeling and lung inflammation in rats, by direct administration into lungs via the airway. Methods BMCs were isolated and plastic-adherent cells were cultured for 3 weeks. 1 week following monocrotaline (60 mg/kg) treatment, fluorescently labeled autologous BMCs (1 x 10.sup.6 cells) or vehicle were administered intratracheally to male Sprague-Dawley rats. 4 weeks following monocrotaline treatment, lung pathology was evaluated. Results Monocrotaline increased pulmonary vessel wall thickness, perivascular infiltration, alveolar septal thickening, and inflammatory cell infiltration including T lymphocytes and monocytes/macrophages in alveolar areas, and also increased mRNA expression of inflammatory-related cytokines including IL-10 in the lung. Intratracheal administration of autologous BMCs prevented pulmonary vessel wall thickening and perivascular infiltration, and increased CD163-positive M2-like macrophages in perivascular areas. BMC administration inhibited the thickening of alveolar septa and reduced monocrotaline-induced inflammatory cell infiltration in lung parenchyma compared with monocrotaline-vehicle-treated-rats. Furthermore, BMCs administration increased expression of CD163-positive cells in perivascular areas and maintained the increased mRNA expression of IL-10. Conclusions Intratracheal administration of autologous BMCs prevented monocrotaline-induced pulmonary vessel remodeling and lung inflammation, at least in part, through induction of alternatively activated macrophages and regulation of the local lung environment toward resolving inflammation., Author(s): Yoriko Yamazato [sup.1] , Masanobu Yamazato [sup.2] , Akio Ishida [sup.2] , Jiro Fujita [sup.1] , Yusuke Ohya [sup.2] Author Affiliations: (Aff1) 0000 0001 0685 5104, grid.267625.2, Department of [...]

Published
2018
Full Text
View/download PDF

39. Confounding effects of microbiome on the susceptibility of TNFSF15 to Crohn’s disease in the Ryukyu Islands

Author

Nakagome, Shigeki, Chinen, Hiroshi, Iraha, Atsushi, Hokama, Akira, Takeyama, Yasuaki, Sakisaka, Shotaro, Matsui, Toshiyuki, Kidd, Judith R., Kidd, Kenneth K., Said, Heba S., Suda, Wataru, Morita, Hidetoshi, Hattori, Masahira, Hanihara, Tsunehiko, Kimura, Ryosuke, Ishida, Hajime, Fujita, Jiro, Kinjo, Fukunori, Mano, Shuhei, and Oota, Hiroki

Published
2017
Full Text
View/download PDF

44. Effect of voluntary human mobility restrictions on vector-borne diseases during the COVID-19 pandemic in Japan: A descriptive epidemiological study using a national database (2016 to 2021).

Author

Hibiya, Kenji, Shinzato, Akira, Iwata, Hiroyoshi, Kinjo, Takeshi, Tateyama, Masao, Yamamoto, Kazuko, and Fujita, Jiro

Subjects
COVID-19 pandemic, VECTOR-borne diseases, COVID-19, TICK-borne diseases, ENDEMIC diseases, MOSQUITO control
Abstract

The coronavirus disease 2019 (COVID-19) pandemic not only encouraged people to practice good hygiene but also caused behavioral inhibitions and resulted reduction in both endemic and imported infectious diseases. However, the changing patterns of vector-borne diseases under human mobility restrictions remain unclear. Hence, we aimed to investigate the impact of transborder and local mobility restrictions on vector-borne diseases through a descriptive epidemiological study. The analysis was conducted using data from the National Epidemiological Surveillance of Infectious Diseases system in Japan. We defined the pre-pandemic period as the period between the 1st week of 2016 to the 52nd week of 2019 and defined the pandemic period as from the 1st week of 2020 to the 52nd week of 2021, with the assumption that human mobility was limited throughout the pandemic period. This study addressed 24 diseases among notifiable vector borne diseases. Datasets were obtained from weekly reports from the National Epidemiological Surveillance of Infectious Diseases, and the incidence of each vector-borne disease was examined. Interrupted time series analysis was conducted on the epidemic curves for the two periods. Between the pre- and post-pandemic periods, the incidence of dengue fever and malaria significantly decreased, which may be related to limited human transboundary mobility (p = 0.003/0.002). The incidence of severe fever with thrombocytopenia syndrome, scrub typhus, and Japanese spotted fever did not show changes between the two periods or no association with human mobility. This study suggests that behavioral control may reduce the incidence of new mosquito-borne diseases from endemic areas but may not affect tick-borne disease epidemics within an endemic area. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Prolonged gut microbial alterations in post‐transplant survivors of allogeneic haematopoietic stem cell transplantation.

Author

Hino, Akihisa, Fukushima, Kentaro, Kusakabe, Shinsuke, Ueda, Tomoaki, Sudo, Takao, Fujita, Jiro, Motooka, Daisuke, Takeda, Aya K., Shinozaki, Natsuko O., Watanabe, Satoshi, Yokota, Takafumi, Shibayama, Hirohiko, Nakamura, Shota, and Hosen, Naoki

Subjects
HEMATOPOIETIC stem cell transplantation, GUT microbiome, GRAFT versus host disease, MICROBIAL diversity
Abstract

Summary: Dysbiosis of the gut microbiota has been reported to increase early complications after allogeneic haematopoietic stem cell transplantation (allo‐HSCT). However, it remains unclear whether gut microbial alterations persist during late complications, such as chronic graft‐versus‐host disease (cGVHD) or secondary cancers. Here, we analysed the gut microbiota of 59 patients who survived for 1–21.7 years (median, 6.4 years) after allo‐HSCT. Long‐term survivors showed lower gut microbial diversity than the age‐ and sex‐matched healthy controls. This decreased diversity was reflected in the reduced abundance of the butyrate‐producing bacteria. Patients with a history of grade 3 acute graft‐versus‐host disease (aGVHD) exhibited higher Veillonella abundance than patients with a history of grade 1–2 or non‐aGVHD cases. The abundance of Faecalibacterium showed no decrease only in limited cGVHD cases. Additionally, the microbial structure in the secondary cancer group was significantly different (p < 0.05) from that in the non‐secondary cancer group. This study is the first to show that microbial dysbiosis is present over a 10‐year lifetime after discharge following allo‐HSCT. Our results suggest that these prolonged gut microbial alterations may be associated with the development and exacerbation of late complications in post‐transplant survivors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results